منابع مشابه
TaqI RFLP polymorphism of the ovine complement component C4 gene.
Protocol: Reactions were performed as described (2) using 1 ng of DNA and 100 pmoles of each primer. DNA was amplified for 20 cycles using a Perkin Elmer Cetus DNA Thermal Cycler: denaturation, 94°C, 1 min; annealing, 60°C, 1 min; and extension, 70°C, 1.5 min. Ten /il of the reaction was analyzed directly on a 2.5 % NuSieve GTG agarose gel run in Tns-borate buffer. The amplified DNA fragments v...
متن کاملA Taqi RFLP of the human TGF alpha gene is significantly associated with cutaneous malignant melanoma.
A TaqI restriction fragment length polymorphism (RFLP) of the human transforming growth factor alpha (hTGF alpha) locus was analyzed in DNA from 63 normal individuals, 34 malignant melanoma (MM) cell lines, and 18 melanoma biopsy specimens. The frequency of a 2.7-kb allele (0.18) in MM cell lines was significantly higher (p less than 0.01) than in lymphoblastoid cell lines (LCLs) derived from u...
متن کاملTaqI RFLP at D21S137.
Chromosomal Localization: The 3 polymorphic bands were mapped to chromosome 22 using a somatic cell hybrid panel. The 2.1 kb constant band mapped to chromosome lq whereas all other constant bands mapped to chromosome 20. Whereas the active gene for hTOPl is located on chromosome 20ql 1.2—13.1, two pseudogenes are on chromosomes Iq23—24 and 22qll.2-13.1 (2). The sequences of hTOPl and the two ps...
متن کاملA TaqI polymorphism in the human cyclin A gene.
PCR Conditions: The PCR reaction is carried out in a total volume of 50 /*1 containing approximately 250 ng DNA, 2 units Taq DNA polymerase, 50 pmol of each primer, 200 /M dNTP's, 10 mM Tris-HCl pH 8.3, 50 mM KC1, 1.5 mM MgCl2, 0.001% gelatin. The amplification is performed for 30 cycles with an annealing temperature of 60°C. The amplified product is digested with TaqI and the DNA fragments are...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nucleic Acids Research
سال: 1989
ISSN: 0305-1048,1362-4962
DOI: 10.1093/nar/17.21.8900